Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1954;9:540-546

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FREIS, E. D.
Right arrow Articles by ROSE, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FREIS, E. D.
Right arrow Articles by ROSE, J. C.

(Circulation. 1954;9:540.)
© 1954 American Heart Association, Inc.


A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

EDWARD D. FREIS M.D.1; EDWARD A. PARTENOPE M.D.1; LAWRENCE S. LILIENFIELD M.D.1; JOHN C. ROSE M.D.1

1 From The Cardiovascular Research Laboratory, Georgetown University Hospital, the Department of Medicine, Georgetown University School of Medicine, and the Veterans Administration Hospital, Washington, D. C.

The new ganglionic blocking agent, pentapyrrolidinium or M&B 2050, appears to have several distinct advantages over hexamethonium in the treatment of severe hypertension. These advantages include longer duration of action, greater potency, less tolerance, less interference with intestinal motility, and, most important, a more uniform response from day to day on oral administration. However, critical adjustment of dosage is necessary and side effects are not infrequent, the most disturbing being postural faintness and impotence.




This article has been cited by other articles:


Home page
ANGIOLOGYHome page
M. A. Lindauer and J. H. Hafken Schiel
Hexamethonium Chloride With Reserpine in the Treatment of Severe Essential Hypertension
Angiology, February 1, 1958; 9(1): 19 - 23.
[PDF]


Home page
Arch Intern MedHome page
E. D. FREIS and I. M. WILSON
Mecamylamine, a New, Orally Effective, Experimental and Clinical Evaluation
Arch Intern Med, May 1, 1956; 97(5): 551 - 561.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
W. M. KIRKENDALL and J. W. CULBERTSON
MANAGEMENT OF SYSTEMIC ARTERIAL HYPERTENSION
Arch Intern Med, April 1, 1955; 95(4): 601 - 613.
[Abstract] [PDF]